Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma1. Issue 2 (14th September 2012)

• Record Type: Journal Article
• Authors: Baraniskin, Alexander; Nöpel‐Dünnebacke, Stefanie; Ahrens, Maike; Jensen, Steffen Grann; Zöllner, Hannah; Maghnouj, Abdelouahid; Wos, Alexandra; Mayerle, Julia; Munding, Johanna; Kost, Dennis; Reinacher‐Schick, Anke; Liffers, Sven; Schroers, Roland; Chromik, Ansgar M.; Meyer, Helmut E.; Uhl, Waldemar; Klein‐Scory, Susanne; Weiss, Frank U.; Stephan, Christian; Schwarte‐Waldhoff, Irmgard; Lerch, Markus M.; Tannapfel, Andrea; Schmiegel, Wolff; Andersen, Claus Lindbjerg; Hahn, Stephan A.
• Is Part Of: International journal of cancer. Volume 132:Issue 2(2013:Jan. 15)
• Page Start: E48
• Page End: E57
• Publication Date: 2012-09-14
• Subjects: Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.27791
• Languages: English
• ISSNs: 0020-7136

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <p>Improved non‐invasive strategies for early cancer detection are urgently needed to reduce morbidity and mortality. Non‐coding RNAs, such as microRNAs and small nucleolar RNAs, have been proposed as biomarkers for non‐invasive cancer diagnosis. Analyzing serum derived from nude mice implanted with primary human pancreatic ductal adenocarcinoma (PDAC), we identified 15 diagnostic microRNA candidates. Of those miR‐1246 was selected based on its high abundance in serum of tumor carrying mice. Subsequently, we noted a cross reactivity of the established miR‐1246 assays with RNA fragments derived from U2 small nuclear RNA (RNU2‐1). Importantly, we found that the assay signal discriminating tumor from controls was derived from U2 small nuclear RNA (snRNA) fragments (RNU2‐1f) and not from miR‐1246. In addition, we observed a remarkable stability of RNU2‐1f in serum and provide experimental evidence that hsa‐miR‐1246 is likely a pseudo microRNA. In a next step, <italic>RNU2‐1f</italic> was measured by qRT‐PCR and normalized to <italic>cel‐54</italic> in 191 serum/plasma samples from PDAC and colorectal carcinoma (CRC) patients. In comparison to 129 controls, we were able to classify samples as cancerous with a sensitivity and specificity of 97.7% [95% CI = (87.7, 99.9)] and 90.6% [95% CI = (80.7, 96.5)], respectively [area under the ROC curve 0.972]. Of note, patients with CRC were detected with our assay as early as UICC Stage II with a sensitivity of 81%. In conclusion, this is the first report showing that fragments of U2 snRNA are highly stable in serum and plasma and may serve as novel diagnostic biomarker for PDAC and CRC for future prospective screening studies.</p> </abstract>